[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06344026":3,"trial-entities:NCT06344026":171,"trial-summary:NCT06344026":174},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":26,"primary_purpose":27,"phases":28,"enrollment_info":30,"interventions":33,"primary_outcomes":44,"secondary_outcomes":49,"sex":65,"minimum_age":66,"maximum_age":67,"healthy_volunteers":68,"eligibility_criteria":69,"std_ages":92,"locations":95,"central_contacts":164,"overall_officials":165,"references":169,"see_also_links":170},"NCT06344026","ANPD001-02","Phase 1\u002F2a Study of ANPD001 in Parkinson Disease","Phase 1\u002F2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease","ENROLLING_BY_INVITATION","2030-04-30","2026-05","2026-05-14","2024-01-23","Aspen Neuroscience","INDUSTRY",true,"This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.","Participants will undergo a surgical implantation of cells that will mature into dopamine-producing neurons under general anesthesia into a part of the brain where dopamine production is decreased in patients with Parkinson Disease. The effect on Parkinson Disease symptoms, safety and tolerability, and cell survival are assessed for 5 years post-transplant (with MRI and PET imaging scans of the brain). Safety and tolerability are assessed annually for an additional 10 years via telephone call (total follow-up of 15 years)",[19],"Parkinson Disease",[21,22,23,24,25],"Autologous","Induced Pluripotent Stem Cells","Cell Therapy","Dopamine","Regenerative Medicine","INTERVENTIONAL","TREATMENT",[29],"PHASE1",{"count":31,"type":32},9,"ESTIMATED",[34,39],{"type":35,"name":36,"description":37,"armGroupLabels":38},"BIOLOGICAL","ANPD001","Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.",[36],{"type":40,"name":41,"description":42,"armGroupLabels":43},"DEVICE","Custom Device","A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance",[36],[45],{"measure":46,"description":47,"timeFrame":48},"Incidence and severity of treatment emergent adverse events (Safety and Tolerability)","incidence and severity of treatment emergent adverse events (TEAE) and serious adverse events (SAE)","1 year (primary follow up)",[50,53,56,59,62],{"measure":51,"timeFrame":52},"\"ON\" time without troublesome dyskinesia","1 year (primary follow up) and 5 years (long term follow up)",{"measure":54,"description":55,"timeFrame":52},"Post-injection change in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II (Activities of Daily Living - ADL) and Part III (motor score) in the ON state (total score and scores for Parts I-IV)","Part II score range is 0 to 52 with 0 being normal and 30 and above being severe",{"measure":57,"description":58,"timeFrame":52},"Post-injection change in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score in the practically defined OFF state","Part III score range is 0 to 132 with 0 being normal and 59 and above being severe",{"measure":60,"description":61,"timeFrame":52},"Post-injection change in the 18F-DOPA uptake in the putamen","Post-injection change in the 18-fluorodopa uptake in the putamen from baseline via positron emission tomography (PET)",{"measure":63,"timeFrame":64},"Incidence and severity of treatment emergent adverse events during long term follow-up (Continued Safety and Tolerability)","14 years of long term follow up (4 years in-person visits and 10 additional years follow up via telephone call)","ALL","40 Years","75 Years",false,{"inclusion":70,"exclusion":75,"raw_text":91},[71,72,73,74],"Age 40-75 years of age at time of consent in the trial-ready cohort study ANPD001-01","Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01","Diagnosed with Parkinson Disease at least 4 years ago","Unequivocal motor response to Levodopa",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90],"Prior brain surgery that, in the opinion of the neurologist or neurosurgeon, contraindicates administration of ANPD001","History of intracranial therapy for PD, including deep brain stimulation (DBS), focused ultrasound (FUS), gene therapy or other biological therapy","History of cognitive impairment or dementia","History of clinically significant Dopa Dysregulation syndrome","History of epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological disease (other than PD), or poorly controlled cardiovascular disease","Inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks","History of malignancy (cerebral or systemic) within the prior 5 years, except treated cutaneous squamous or basal cell carcinomas","Contraindication to MRI \u002F contrast CRT and\u002For use of contrast agents","Weight \\> 300 lbs or Body Mass Index (BMI) \\> 35","Newly diagnosed diabetes (HbA1c \\> 7.0%), uncontrolled diabetes \\> 8.0% requiring frequent medication changes, or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure","Pregnancy or lactation","Significant drug-induced dyskinesia (\\> 3 for any body part on the Abnormal Involuntary Movement Scale \\[AIMS\\])","Male or female with reproductive capacity who is unwilling to use barrier contraception for 3 months post-administration of the investigational product","Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments","Any significant issue raised by the neurologist or neurosurgeon","Inclusion Criteria:\n\n* Age 40-75 years of age at time of consent in the trial-ready cohort study ANPD001-01\n* Met all eligibility requirements for inclusion in the trial-ready cohort in clinical study ANPD001-01\n* Diagnosed with Parkinson Disease at least 4 years ago\n* Unequivocal motor response to Levodopa\n\nExclusion Criteria:\n\n* Prior brain surgery that, in the opinion of the neurologist or neurosurgeon, contraindicates administration of ANPD001\n* History of intracranial therapy for PD, including deep brain stimulation (DBS), focused ultrasound (FUS), gene therapy or other biological therapy\n* History of cognitive impairment or dementia\n* History of clinically significant Dopa Dysregulation syndrome\n* History of epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological disease (other than PD), or poorly controlled cardiovascular disease\n* Inability to temporarily stop anticoagulation or antiplatelet therapy for at least 2 weeks\n* History of malignancy (cerebral or systemic) within the prior 5 years, except treated cutaneous squamous or basal cell carcinomas\n* Contraindication to MRI \u002F contrast CRT and\u002For use of contrast agents\n* Weight \\> 300 lbs or Body Mass Index (BMI) \\> 35\n* Newly diagnosed diabetes (HbA1c \\> 7.0%), uncontrolled diabetes \\> 8.0% requiring frequent medication changes, or any other acute or chronic medical condition that would significantly increase the risks of a neurosurgical procedure\n* Pregnancy or lactation\n* Significant drug-induced dyskinesia (\\> 3 for any body part on the Abnormal Involuntary Movement Scale \\[AIMS\\])\n* Male or female with reproductive capacity who is unwilling to use barrier contraception for 3 months post-administration of the investigational product\n* Unable to comply with the protocol procedures, including frequent and prolonged follow-up assessments\n* Any significant issue raised by the neurologist or neurosurgeon",[93,94],"ADULT","OLDER_ADULT",[96,105,113,120,127,133,140,148,156],{"facility":97,"city":98,"state":99,"zip":100,"country":101,"geoPoint":102},"University of Arizona - Banner Health","Tucson","Arizona","85724","United States",{"lat":103,"lon":104},32.22174,-110.92648,{"facility":106,"city":107,"state":108,"zip":109,"country":101,"geoPoint":110},"Scripps Health","La Jolla","California","92037",{"lat":111,"lon":112},32.84727,-117.2742,{"facility":114,"city":115,"state":108,"zip":116,"country":101,"geoPoint":117},"University of California, Los Angeles","Los Angeles","90095",{"lat":118,"lon":119},34.05223,-118.24368,{"facility":121,"city":122,"state":108,"zip":123,"country":101,"geoPoint":124},"University of California, Irvine","Orange","92868",{"lat":125,"lon":126},33.78779,-117.85311,{"facility":128,"city":129,"state":108,"zip":109,"country":101,"geoPoint":130},"University of California, San Diego","San Diego",{"lat":131,"lon":132},32.71571,-117.16472,{"facility":134,"city":135,"state":108,"zip":136,"country":101,"geoPoint":137},"University of California, San Francisco","San Francisco","94143",{"lat":138,"lon":139},37.77493,-122.41942,{"facility":141,"city":142,"state":143,"zip":144,"country":101,"geoPoint":145},"University of Colorado","Aurora","Colorado","80045",{"lat":146,"lon":147},39.72943,-104.83192,{"facility":149,"city":150,"state":151,"zip":152,"country":101,"geoPoint":153},"Emory University","Atlanta","Georgia","30322",{"lat":154,"lon":155},33.749,-84.38798,{"facility":157,"city":158,"state":159,"zip":160,"country":101,"geoPoint":161},"Feinstein Institutes","Manhasset","New York","11030",{"lat":162,"lon":163},40.79788,-73.69957,[],[166],{"name":167,"affiliation":13,"role":168},"Revati Shreeniwas, MD, FCCP","STUDY_CHAIR",[],[],{"nct_id":4,"conditions":172,"biomarkers":173},[19],[],{"nct_id":4,"found":68,"summary":175,"prompt_version":175},null]